Current Research in Biological Sciences (2025);1(1): 01-08 **ISSN: XXXX-XXXX**

REVIEW PAPER

Inclusive Healthcare Approaches for HIV-Positive Sickle Cell Disease Patients: A Review

Emmanuel Ifeanyi Obeagu[1] and Priya Homa Chukwu[2]
[1]*Department of Biomedical and Laboratory Science, Africa University, Zimbabwe,* emmanuelobeagu@yahoo.com, obeague@africau.edu, ORCID: 0000-0002-4538-0161
[2]*Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science, Rivers State University of Science and Technology, Port Harcourt, Rivers State, Nigeria, ORCID: 0000-0002-1538-2924*
[*]*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, E-mail:* emmanuelobeagu@yahoo.com, obeague@africau.edu, *ORCID: 0000-0002-4538-0161*

Abstract: *HIV-positive individuals with Sickle Cell Disease (SCD) face unique medical challenges due to the interplay between immune dysfunction, chronic inflammation, and vaso-occlusive complications. The co-existence of these conditions increases susceptibility to infections, worsens disease progression, and complicates treatment strategies. Standard HIV care must be adapted to address the distinct needs of SCD patients, including careful selection of antiretroviral therapy (ART) to minimize adverse effects and drug interactions. Without an inclusive healthcare approach, these patients remain at risk for poor health outcomes and increased mortality. Inclusive healthcare strategies prioritize multidisciplinary care models that integrate infectious disease specialists, hematologists, pain management experts, and mental health professionals. Such models enhance comprehensive disease management by addressing both physiological and psychosocial needs. Additionally, culturally competent and patient-centered care is essential for improving treatment adherence and mitigating stigma. Expanding healthcare access through specialized clinics, mobile health services, and telemedicine can further bridge disparities in care for this vulnerable population.*

Keywords: *HIV, Sickle Cell Disease, Inclusive Healthcare, Multidisciplinary Care, Health Equity.*

1 INTRODUCTION

HIV and Sickle Cell Disease (SCD) are two chronic conditions that disproportionately affect populations in sub-Saharan Africa and African American communities. While HIV is an acquired immunodeficiency disorder caused by the Human Immunodeficiency Virus, SCD is a hereditary blood disorder characterized by abnormal hemoglobin, leading to vaso-occlusive episodes, chronic anemia, and multi-organ complications. The

co-existence of these two conditions presents significant healthcare challenges, requiring an inclusive and multidisciplinary approach to treatment and management.[1-3] Individuals living with both HIV and SCD experience a heightened burden of disease due to overlapping complications, including increased susceptibility to infections, chronic inflammation, and the potential for adverse drug interactions. HIV further compromises immune function, making SCD patients more vulnerable to opportunistic infections and delayed recovery from vaso-occlusive crises. Additionally, some antiretroviral therapy (ART) regimens may exacerbate SCD complications, such as bone marrow suppression and anemia, necessitating careful treatment selection.[4-6] The social determinants of health play a crucial role in the healthcare challenges faced by HIV-positive SCD patients. Socioeconomic disparities, stigma, and limited healthcare access often prevent timely diagnosis and effective disease management. Many patients experience barriers to care, including financial constraints, transportation difficulties, and a lack of specialized healthcare providers. Addressing these disparities requires a holistic healthcare approach that incorporates patient education, community support, and policy-driven initiatives aimed at improving access to specialized care.[7-9]

Pain management is another critical aspect of care for HIV-positive SCD patients. SCD is associated with frequent and severe pain episodes that often require opioid therapy, which can complicate HIV treatment due to potential drug interactions and concerns about dependency. Additionally, HIV-related neuropathy may contribute to chronic pain, necessitating individualized and comprehensive pain management strategies that include both pharmacological and non-pharmacological interventions.[10-12] Mental health support is essential for individuals living with both conditions, as they often face significant emotional distress, depression, and anxiety. The stigma surrounding both HIV and SCD can lead to social isolation and reduced treatment adherence. Integrating psychological support services into routine care can enhance patient well-being, improve adherence to medications, and ultimately lead to better health outcomes.[13-14] Healthcare systems must adopt an inclusive approach that fosters collaboration between hematologists, infectious disease specialists, pain management teams, mental health professionals, and social workers. By leveraging a team-based approach, clinicians can provide personalized and holistic care that addresses the unique needs of this patient population. Furthermore, advancements in medical research, including gene therapies for SCD and long-acting ART regimens, offer hope for improved disease management in the future.[15-17] This review explores the intersection of HIV and SCD, highlighting the challenges, current management strategies, and the need for an inclusive healthcare framework.

2 THE BURDEN OF HIV AND SICKLE CELL DISEASE CO-EXISTENCE

2.1. Epidemiology and Prevalence

The co-existence of HIV and Sickle Cell Disease (SCD) presents a significant public health challenge, particularly in regions where both conditions are prevalent. Sub-Saharan Africa bears the highest burden of SCD, with an estimated 300,000 infants born with the disease annually, while the region also accounts for nearly two-thirds of the global HIV burden. The overlap in these disease populations is largely driven by high HIV prevalence in areas where SCD is endemic, leading to an increasing number of individuals living with both conditions. Despite this growing patient population, there is limited epidemiological data on the exact prevalence and health outcomes of

individuals with co-existing HIV and SCD, highlighting a critical gap in research and healthcare planning.[18-20]

2.2. Clinical and Immunological Implications

The interaction between HIV and SCD significantly impacts disease progression and patient outcomes. HIV weakens the immune system, increasing susceptibility to bacterial infections, which are already a leading cause of morbidity and mortality in SCD patients. Additionally, chronic inflammation from both conditions exacerbates vascular dysfunction, heightening the risk of vaso-occlusive crises and end-organ damage. Furthermore, anemia, a hallmark of SCD, can be worsened by HIV-related complications such as bone marrow suppression, nutritional deficiencies, and opportunistic infections, leading to more severe disease manifestations.[21-22]

2.3. Challenges in Antiretroviral Therapy (ART) and SCD Management

The management of HIV in SCD patients is complicated by potential drug interactions and treatment side effects. Many ART regimens can exacerbate SCD-related complications, such as anemia, hepatotoxicity, and mitochondrial toxicity. For example, zidovudine (AZT) and other nucleoside reverse transcriptase inhibitors (NRTIs) can contribute to bone marrow suppression, worsening the chronic anemia seen in SCD. Additionally, hydroxyurea, a common therapy for SCD that reduces the frequency of vaso-occlusive crises, may have overlapping hematologic toxicities with ART. Clinicians must carefully balance treatment options to optimize patient outcomes while minimizing adverse effects.[23-25]

2.4. Increased Risk of Organ Damage and Mortality

HIV and SCD both contribute to multi-organ dysfunction, particularly affecting the kidneys, liver, heart, and lungs. Chronic hemolysis in SCD leads to endothelial damage and increased oxidative stress, which, when compounded by HIV-related inflammation, accelerates organ deterioration. HIV-associated nephropathy (HIVAN) is of particular concern, as SCD patients already have a high risk of kidney disease due to repeated episodes of ischemia-reperfusion injury and glomerular hyperfiltration. Similarly, pulmonary hypertension, a known complication of SCD, may be exacerbated by HIV, further increasing the risk of early mortality in co-infected individuals.[26-28]

2.5. Socioeconomic and Psychosocial Challenges

Beyond the medical complexities, individuals with both HIV and SCD often face significant socioeconomic and psychosocial challenges. Stigma associated with both conditions can lead to social isolation, discrimination, and reduced access to healthcare services. Financial burdens related to frequent hospitalizations, medication costs, and specialized care further complicate disease management. Additionally, mental health concerns such as depression and anxiety are prevalent in this population, affecting treatment adherence and overall quality of life. Addressing these challenges requires a holistic healthcare approach that integrates medical, psychological, and social support services.[29-31]

2.6. The Need for Inclusive Healthcare Approaches

Given the multifaceted burden of HIV and SCD co-existence, healthcare systems must

adopt an inclusive and multidisciplinary care model. Integrating infectious disease specialists, hematologists, nephrologists, mental health professionals, and social workers into patient care can improve disease outcomes and enhance overall well-being. Public health initiatives should focus on increasing awareness, promoting early diagnosis, and improving healthcare access for individuals with both conditions. Additionally, further research is needed to better understand disease interactions and optimize treatment protocols for this vulnerable population.[32-34]

3. INCLUSIVE HEALTHCARE STRATEGIES

Addressing the complex healthcare needs of HIV-positive individuals with Sickle Cell Disease (SCD) requires an inclusive, patient-centered approach that integrates multidisciplinary care, culturally competent practices, and equitable healthcare access. Given the overlapping complications of both conditions, healthcare systems must implement comprehensive strategies to improve patient outcomes, enhance quality of life, and reduce healthcare disparities.[35]

3.1. Multidisciplinary Care Models

An integrated healthcare approach involving hematologists, infectious disease specialists, pain management experts, nephrologists, psychologists, and social workers is essential for managing the co-existence of HIV and SCD. Regular consultations and coordinated care plans help optimize treatment regimens, minimize drug interactions, and address both physical and mental health needs. Multidisciplinary clinics that provide both HIV and SCD management under one setting can significantly improve patient adherence and reduce hospital visits.[35-37]

3.2. Culturally Competent and Patient-Centered Care

Many patients living with HIV and SCD face stigma, discrimination, and cultural barriers that impact their willingness to seek medical care. Culturally competent healthcare ensures that providers understand the unique social and cultural factors influencing patient behavior. Training healthcare workers in culturally sensitive communication, providing multilingual educational materials, and involving community leaders in health initiatives can foster trust and encourage patient engagement.[38-40]

3.3. Pain Management and Palliative Care

Pain is a significant burden in SCD, and its management is further complicated by HIV-related neuropathy. An inclusive approach to pain management should incorporate a combination of pharmacological and non-pharmacological interventions, including individualized opioid regimens, physical therapy, cognitive-behavioral therapy, and complementary medicine. Providers must also be mindful of opioid dependence risks and explore alternative pain relief strategies to improve long-term patient well-being.[41]

3.4. Improving Access to Care and Health Equity

Patients with both HIV and SCD often face socioeconomic barriers that limit access to timely and specialized care. Expanding healthcare access through mobile health services, telemedicine, and community-based programs can help reach underserved populations. Government policies should support subsidized treatment programs, increase the availability of essential medications, and invest in specialized centers that provide integrated care for co-infected individuals.[42-43]

3.5. Advancements in Research and Therapeutic Innovations

Emerging treatments, including gene therapy for SCD and long-acting injectable antiretroviral therapy (ART), offer promising solutions for improving disease management in co-infected patients. Research should focus on optimizing ART regimens that minimize complications for SCD patients, exploring new pain management options, and understanding the long-term effects of co-existing HIV and SCD. Clinical trials should also prioritize inclusivity by ensuring diverse representation of affected populations.[44-45]

3.6. Mental Health and Psychosocial Support

Mental health services should be an integral part of inclusive healthcare for HIV-positive SCD patients. Depression, anxiety, and stress are common in this population due to chronic illness, stigma, and social isolation. Counseling services, peer support groups, and psychosocial interventions can help improve emotional well-being, enhance treatment adherence, and empower patients to manage their conditions more effectively.[46]

3.7. Community Engagement and Public Health Initiatives

Community-based programs play a crucial role in raising awareness, reducing stigma, and improving healthcare utilization among patients with HIV and SCD. Public health campaigns should focus on education about disease co-existence, early screening, and the importance of adherence to treatment. Strengthening community partnerships can also facilitate patient navigation through healthcare systems, ensuring better access to resources and support networks.[47-48]

4. CONCLUSION

The co-existence of HIV and Sickle Cell Disease (SCD) presents a unique and complex healthcare challenge, requiring an inclusive, patient-centered approach to disease management. The interplay between immune dysfunction, chronic inflammation, and vaso-occlusive complications increases morbidity and mortality in affected individuals. Standard treatment protocols must be adapted to account for overlapping complications, potential drug interactions, and the heightened vulnerability of this population to infections and organ damage. Without a comprehensive strategy, these patients remain at high risk for poor health outcomes and reduced quality of life. Inclusive healthcare strategies emphasize multidisciplinary collaboration, culturally competent care, and equitable access to essential medical services. Integrating infectious disease specialists, hematologists, mental health professionals, and pain management teams into routine care improves treatment outcomes and enhances patient well-being. Additionally, expanding healthcare access through mobile health services, telemedicine, and specialized clinics ensures that vulnerable populations receive timely and appropriate medical attention. Addressing social determinants of health, such as stigma, financial barriers, and mental health concerns, further strengthens disease management efforts.

5. REFERENCES

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. Clinical Infectious Diseases. 2015; 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis.

Transfusion Medicine Reviews. 2019; 33(3):162-169.
3. Ola B, Olushola O, Ebenso B, Berghs M. Sickle Cell Disease and Its Psychosocial Burdens in Africa. InSickle Cell Disease in Sub-Saharan Africa 2024: 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. The scientific world journal. 2013; 2013(1):193252.
5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Frontiers in Pediatrics. 2020; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology, 2024; 2(1): 14-33
7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024; 10(1):25-36.
10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Asian J Dental Health Sci, 2024; 4(1):32-7. Available from: http://ajdhs.com/index.php/journal/article/view/62
11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
13. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73 1
14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20- 35
15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIVExposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport International Journal of Biological and Applied Sciences (NIJBAS) 2023. http://hdl.handle.net/20.500.12493/14626
17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation. 2023; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circulation research. 2024; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, Hileman CO, Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences. 2024; 25(13):7266..
20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases. 2020; 20(1):638.
23. Bhowmik A, Banerjee P. Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak. 2015; 25(2):119-123.
24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic abnormalities associated with simian immunodeficieny virus (SIV)

infection mimic those in HIV infection. Journal of Medical Primatology. 2012; 41(3):214-224.
25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. Sexually transmitted infections. 2012; 88(7):528-533.
.Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024; 2(1):33-45.
26. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
27. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
28. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
29. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
30. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies . Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
31. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
32. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
33. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
34. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
35. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
36. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy. 2015; 12:1-8.
37. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC hematology. 2014; 14:1-7.
38. Gudina A, Wordofa M, Urgessa F. Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. Plos one. 2024; 19(10):e0310239.
39. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine. 2017:99-105.
40. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233.
41. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024; 2(4):68-85.
42. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
43. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi

MC. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020; 15(11):e0242068.
44. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554.
45. Obeagu EI, Goryacheva OG. The Role of Inflammation in HIV and Sickle Cell Disease Co-Morbidity. Lifeline HIV, 2025; 3(1): 1-12
46. Obeagu EI, Goryacheva OG. Oxidative Stress in HIV and Sickle Cell Disease: A Double Burden. Lifeline HIV, 2025; 3(1): 13-24
47. Obeagu EI, Goryacheva OG. HIV and Sickle Cell Disease: A Focus on Liver Dysfunction. Lifeline HIV, 2025; 3(1): 25-40